Ibisubizo Byibanze bya CD7-Intego CAR-T ivura T-BYOSE na T-LBL

Igeragezwa rya kliniki iherutse kwerekana iterambere ryinshi mu kuvura T-selile acute lymphoblastique leukemia (T-ALL) na Lymphoblastique lymphoma (T-LBL) ikoresheje CD7 yibasiwe na chimeric antigen reseptor (CAR) T. . Ubu bushakashatsi bwakozwe nitsinda ryaturutse mu bitaro bya Hebei Yanda Lu Daopei n’ikigo cya Lu Daopei Institute of Hematology, cyitabiriwe n’abarwayi 60 bahawe ikinini kimwe cy’ingirabuzimafatizo zatoranijwe zirwanya CD7 CAR (NS7CAR) T.

Ibisubizo by'ibigeragezo birashimishije cyane. Ku munsi wa 28, 94.4% byabarwayi bagezeho neza (CR) mumitsi. Byongeye kandi, mu barwayi 32 barwaye indwara zidasanzwe, 78.1% bagaragaje ko bakiriye neza, aho 56.3% bageze ku gukira burundu naho 21.9% bagera ku gukira igice. Imyaka ibiri muri rusange kubaho no kubaho nta terambere ryabayeho byari 63.5% na 53.7%.

Ubu buryo bushya bwo kuvura bugaragara cyane kubera umutekano wabwo ushobora gucungwa, hamwe na syndrome yo kurekura cytokine igaragara ku barwayi 91.7% (cyane cyane icyiciro cya 1/2), naho neurotoxicity igaragara kuri 5%. Byongeye kandi, ubushakashatsi bwerekanye ko abarwayi batewe no guhuriza hamwe nyuma yo kugera kuri CR bafite umubare munini w’ubuzima bwo kubaho nta terambere ugereranyije n’abatabikoze.

Isosiyete yacu kandi irimo gushakisha uburyo CD7 CAR-T ivura selile hamwe nibicuruzwa byacu bwite, igamije kugira uruhare mu guteza imbere imiti ivura indwara ya T-selile.

Ibyavuye mu bushakashatsi bishimangira ubushobozi bwa CD7 bugenewe kuvura CAR-T kugira ngo butange ibyiringiro bishya ku barwayi bafite T-ALL na T-LBL bongeye kwisubiraho cyangwa bagaruka, ibyo bikaba ari intambwe ikomeye mu ntambara ikomeje kurwanya izo ndwara zitoroshye.